Portal de Periódicos da CAPES

TREATMENT OF CENTRAL NERVOUS SYSTEM CRYPTOCOCCOSIS: A REVIEW AND REPORT OF FOUR CASES TREATED WITH ACTIDIONE

1952; American College of Physicians; Volume: 37; Issue: 1 Linguagem: Inglês

10.7326/0003-4819-37-1-123

1539-3704

Charles A. Carton,

Antimicrobial Resistance in Staphylococcus

Article1 July 1952TREATMENT OF CENTRAL NERVOUS SYSTEM CRYPTOCOCCOSIS: A REVIEW AND REPORT OF FOUR CASES TREATED WITH ACTIDIONECHARLES A. CARTON, M.D.CHARLES A. CARTON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-37-1-123 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONIn a previous review,9the morbidity and mortality of cryptococcosis were discussed. It was shown that infection with the cryptococcus was usually fatal. Of approximately 220 published cases of the disease, 33 cases were alive at the time of their respective reports. Nineteen of these did not have central nervous system disease and, of this group, 13 appeared to have been completely cured; these included bone, scalp, skin, lung and nasopharyngeal lesions. On the other hand, of the 14 cases who were still alive with central nervous system disease, only one could be considered cured. This was the case...Bibliography1. August B, Montefiore Hospital, New York, N. Y.—Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949. Google Scholar2. BaerHoldenSeegalRaymond HMBCS: Personal communication. Google Scholar3. BaerHoldenSeegal HMBC: The nature of the antibacterial agent from Anemone pulsatilla , J. Biol. Chem. 162: 65-68, 1946. CrossrefMedlineGoogle Scholar4. BeckMuntz EMHH: Experimental therapy of generalized torulosis in rats with streptomycin, J. Lab. and Clin. Med. 33: 1159-1161, 1948. MedlineGoogle Scholar5. Benham RW: Cryptococci, their identification by morphology and serology, J. Infect. Dis. 57: 255-274, 1935. CrossrefGoogle Scholar6. BernhardtZalewskiBurawski RGJ: Generalisierte Torulose (Europaische Blastomykose), Arch. f. Dermat. u. Syph. 173: 78-90, 1935. CrossrefGoogle Scholar7. Blair D: Torulosis of the central nervous system, J. Ment. Sc. 89: 42-51, 1943. CrossrefGoogle Scholar8. Brockman DD: In vitro effect of atabrine on Cryptococcus neoformans , Am. J. Trop. Med. 28: 295-297, 1948. CrossrefMedlineGoogle Scholar9. Carton CA: Central nervous system cryptococcosis. In preparation. Google Scholar9a. Carton CA: Neurosurgical aspects of cryptococcosis, J. Neurosurg. 8: 143-156, 1951. CrossrefMedlineGoogle Scholar10. Cawley EP, University of Michigan, Ann Arbor, Michigan—Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949. Google Scholar11. Cohen M: Binocular papilledema in a case of torulosis associated with Hodgkin's disease, Arch. Ophth. 32: 477-497, 1944. CrossrefGoogle Scholar12. Collins VC: Bone involvement in cryptococcosis (torulosis), Am. J. Roentgenol. 63: 102-112, 1950. Google Scholar13. ConantMartinSmithBakerCallaway NFDSDTRDJL: Manual of clinical mycology, 1944, W. B. Saunders & Co., Philadelphia. Google Scholar14. DeCrespigny CT: Torula infection of the central nervous system, M. J. Australia 31 (2): 605-615, 1944. CrossrefGoogle Scholar15. Dienst RB: Cryptococcus histolyticus isolated from subcutaneous tumor, Arch. Dermat. and Syph. 37: 461-464, 1938. CrossrefGoogle Scholar16. DrouhetSegretain EG: The action of hyaluronidase on the capsule of Torula histolytica , Compt. rend. Acad. d. sc. 228: 424-425, 1949. MedlineGoogle Scholar17. EcholsGarcia DJ: Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949; and personal communication. Google Scholar18. Evans EE: The antigenic composition of Cryptococcus neoformans. I. A serologic classification by means of capsular and agglutination reactions, J. Immunol. 64: 423-430, 1950. MedlineGoogle Scholar19. Fisher AM: The clinical picture associated with infections due to Cryptococcus neoformans (Torula histolytica). Report of three cases with some experimental studies, Bull. Johns Hopkins Hosp. 86: 383-414, 1950. MedlineGoogle Scholar20. FlinnHookerScott LBJWEG: Torula histolytica (Cryptococcus neoformans) infection. Report of a case refractory to sulfonamides, Delaware State M. J. 18: 141-147, 1946. MedlineGoogle Scholar21. FordLeach JHBE: Actidione, an antibiotic from Streptomyces griseus , J. Am. Chem. Soc. 70: 1223-1226, 1948 CrossrefMedlineGoogle Scholar22. FordLeachWhiffen JHBEAJ: Actidione, an antibiotic from Streptomyces griseus , J. Am. Chem. Soc. 69: 474, 1947. CrossrefMedlineGoogle Scholar23. GlobusGangBergman JHKMPS: Torula meningoencephalitis, J. Neuropath. and Exper. Neurol. 10: 208-228, 1951. CrossrefGoogle Scholar24. Goldberg LH: Torula infection of the central nervous system. Report of a case with necropsy findings, J. Lab. and Clin. Med. 26: 299-301, 1940. Google Scholar25. GreeningMenville RRLI: Roentgen findings in torulosis, Radiology 48: 381-388, 1947. CrossrefMedlineGoogle Scholar26. Greenwald LM: Personal communication. Google Scholar27. HamiltonThompson LCPE: Treatment of cryptococcic meningitis with penicillin, Am. J. Dis. Child. 72: 334-342, 1946. CrossrefMedlineGoogle Scholar28. HaspelBakerMoore RJMB: Disseminated Cryptococcus neoformans. Case report. New Orleans M. and S. J. 101: 573-575, 1949. Also personal communication and Upjohn Circular, 1949. MedlineGoogle Scholar29. Hellstrom M: Assay of actidione by paper disc method using Cryptococcus neoformans. To be published. Google Scholar30. HellstromSeegal MB: Personal communication. Google Scholar31. Higgins JM, Robert Packer Hospital, Sayre, Pa.—Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949; and personal communication. Google Scholar32. Hill JM, William Buchan Blood Center, Baylor Hospital, Dallas, Texas—Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949. Google Scholar33. HobbyRegnaDoughertyStieg GLPPNWE: The antifungal activity of antibiotic XG, J. Clin. Investigation 28: 927-933, 1949. CrossrefGoogle Scholar34. Hoff CL: Immunity studies of Cryptococcus hominis (Torula histolytica), J. Lab. and Clin. Med. 27: 751-754, 1942. Google Scholar35. HoldenSeegalBaer MBCH: Range of antibiotic activity of protoanemonin, Proc. Soc. Exper. Biol. and Med. 66: 54-60, 1947. CrossrefMedlineGoogle Scholar36. JonesKlinck SHGH: Torula histolytica (Cryptococcus hominis) meningitis; case report and therapeutic experiments, Ann. Int. Med. 22: 736-745, 1945. LinkGoogle Scholar37. KeeneyAjelloLankford ELLE: Studies on common pathogenic fungi and on Actinomyces bovis , Bull. Johns Hopkins Hosp. 75: 393-409, 1944. Google Scholar38. KligmanCraneNorris AMAPRF: Effect of temperature on survival of chick embryos infected intravenously with Cryptococcus neoformans (Torula histolytica), Am. J. M. Sc. 221: 273-278, 1951. CrossrefMedlineGoogle Scholar39. KligmanWeidman AMFD: Experimental studies on treatment of human torulosis, Arch. Dermat. and Syph. 60: 726-741, 1949. CrossrefGoogle Scholar40. KornfeldJones ECRG: The structure of actidione, an antibiotic from Streptomyces griseus , Science 108: 437-438, 1948. CrossrefMedlineGoogle Scholar41. Kuhn LR: Growth and viability of Cryptococcus hominis at mouse and rabbit body temperatures, Proc. Soc. Exper. Biol. and Med. 41: 573-574, 1939. CrossrefGoogle Scholar42. Kuhn LR: Effect of elevated body temperatures on cryptococcosis in mice, Proc. Soc. Exper. Biol. and Med. 71: 341-343, 1949. CrossrefMedlineGoogle Scholar43. LandyWarrenRosenmanColio MGHSBLG: Bacillomycin, an antibiotic from Bacillus subtilis active against pathogenic fungi, Proc. Soc. Exper. Biol. and Med. 67: 539-541, 1948. CrossrefMedlineGoogle Scholar44. Levy I, Medical Arts Building, St. Louis, Mo.—Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949; and personal communication. Google Scholar45. LewisHopperSchultz GMMES: In vitro fungistasis by bacterium (Bacillus substilis var. XG, XY), Arch. Dermat. and Syph. 54: 300-307, 1946. CrossrefGoogle Scholar46. LooSkellThornberryEhrlichMcGuireSavageSylvester YHPSHHJJMGMJC: Assay of streptomycin by paper disc plate method, J. Bact. 50: 701-709, 1945. CrossrefGoogle Scholar47. MarshallTeed MRW: Torula histolytica meningoencephalitis. Recovery following bilateral mastoidectomy and sulfonamide therapy, J. A. M. A. 120: 527-529, 1942. CrossrefGoogle Scholar48. MezeyFowler CMR: Cerebrospinal cryptococcosis, J. A. M. A. 132: 632-634, 1946. CrossrefMedlineGoogle Scholar49. MosbergArnold WHJG: Torulosis of the central nervous system: review of literature and report of five cases, Ann. Int. Med. 32: 1153-1183, 1950. LinkGoogle Scholar50. NeillCastilloSmithKapros JMCGRHCE: Capsular reactions and soluble antigens of Torula histolytica and of Sporotrichum schenkii , J. Exper. Med. 89: 93-105, 1949. CrossrefMedlineGoogle Scholar51. Nichols IC: Torula meningoencephalitis. Report of a case, Rhode Island M. J. 24: 221-222, 1941. Google Scholar52. O'NeillNewcombNielson FLALCS: Cryptococcic meningitis. Report of a case, U. S. Nav. M. Bull. 49: 300-305, 1949. MedlineGoogle Scholar53. Piper JE: A case of torulosis, M. J. Australia 31: 441, 1944. CrossrefGoogle Scholar54. ReevesButtHammock DLBMRW: Torula infection of the lungs and central nervous system; report of six cases with three autopsies, Arch. Int. Med. 68: 57-79, 1941. CrossrefGoogle Scholar55. ReillyArtman EBEL: Cryptococcosis. Report of a case and experimental studies, Arch. Int. Med. 81: 1-8, 1948. CrossrefGoogle Scholar56. ReillySchatzWaksman HCASA: Antifungal properties of antibiotic substances, J. Bact. 49: 585-594, 1945. CrossrefMedlineGoogle Scholar57. RobinsonSmithGraessle HJDGOE: Chemotherapeutic properties of streptomycin, Proc. Soc. Exper. Biol. and Med. 57: 226-231, 1944. CrossrefGoogle Scholar58. Seegal BC: Personal communication. Google Scholar59. SeegalHolden BCM: The antibiotic activity of extracts of Ranunculaceae, Science 101: 413-414, 1945. CrossrefMedlineGoogle Scholar60. Seifter J: Personal communication. Google Scholar61. ShapiroNeal LLJB: Torula meningitis, Arch. Neurol. and Psychiat. 13: 174-190, 1925. CrossrefGoogle Scholar62. Shaw E: A synthesis of protoanemonin, J. Am. Chem. Soc. 68: 2510-2513, 1946. CrossrefMedlineGoogle Scholar63. Sheppe WM: Torula infection in man, Am. J. M. Sc. 167: 91-108, 1934. Google Scholar64. SolotorovskyBugie MEJ: The effect of streptothricin on systemic infection with Cryptococcus neoformans in mice, J. Immunol. 60: 497-502, 1948. MedlineGoogle Scholar65. StoneSturdivant WJBF: Meningo-encephalitis due to Torula histolytica , Arch. Int. Med. 44: 560-565, 1929. CrossrefGoogle Scholar66. SweigertMayer CGKF, Stanford University Medical School and University of California Medical School, San Francisco, California; Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949. Google Scholar67. TinneySchmidt WSHW: Torula infection, M. Clin. North America 28: 950-956, 1944. CrossrefGoogle Scholar68. Toone EC: Torula histolytica (Blastomycoides histolytica) meningitis. Report of a case with recovery, Virginia M. Monthly 68: 405-407, 1941. Google Scholar69. UrbachZach EF: Generalisierte Torulose, Arch. f. Dermat. u. Syph. 162: 401-421, 1930. CrossrefGoogle Scholar70. Upjohn Laboratory Circular, Upjohn Company, Kalamazoo, Michigan, 1949. Google Scholar71. VoylesBeck GQEM: Systemic infection due to Torula histolytica (Cryptococcus hominis). II: Effect of chemotherapeutic agents in experimentally produced infection, Arch. Int. Med. 77: 516-525, 1946. CrossrefGoogle Scholar72. Waksman SA: Microbial antagonisms and antibiotic substances, 1947, The Commonwealth Fund, New York. CrossrefGoogle Scholar73. WaksmanSchatzReilly SAAHC: Metabolism and the chemical nature of Streptomyces griseus , J. Bact. 51: 753-759, 1945. CrossrefGoogle Scholar74. WaltonWoodruff RBHB: A crystalline antifungal agent, mycosubtilin, isolated from subtilin broth, J. Clin. Investigation 28: 924-926, 1949. CrossrefMedlineGoogle Scholar75. WarviRawson WNRW: Torula meningitis, Arch. Int. Med. 69: 90-98, 1942. CrossrefGoogle Scholar76. WhiffenBohanosEmerson AJNRL: The production of an antifungal antibiotic by Streptomyces griseus , J. Bact. 52: 610-611, 1946. CrossrefMedlineGoogle Scholar77. WillardWolff HNHG: Remission as a feature in torulosis, J. Nerv. and Ment. Dis. 112: 237-239, 1950. CrossrefMedlineGoogle Scholar78. WilsonDuryea HMAW: Cryptococcus meningitis (torulosis) treated with a new antibiotic, actidione, Arch. Neurol. and Psychiat. 66: 470-480, 1951. CrossrefMedlineGoogle Scholar79. MarshallTeed MRW: Torula histolytica meningoencephalitis: further report, Ann. Int. Med. 34: 1277-1279 (May) 1951. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication August 22, 1951.From the Departments of Neurology and Neurosurgery, College of Physicians and Surgeons, Columbia University, and the Neurological Institute, Presbyterian Hospital, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPopulation Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal MeningitisTherapy of CryptococcosisPneumocystis and Other Less Common Fungal InfectionsPneumocystis and Other Less Common Fungal InfectionsAnfotericina B no tratamento da neurocriptococose em pacientes submetidos a transplante renalCriptococose do sistema nervoso central: experiência atual do Serviço de Neurologia da Escola Paulista de MedicinaCryptococcosisCryptococcosisCryptococcal MeningitisAmphotericin B in Cryptococcal Meningitis Long-Term Results of TreatmentGEORGE A. SAROSI, M.D., JAMES D. PARKER, M.D., IRENE L. DOTO, M.A., FRED E. TOSH, M.D.Cryptococcosis: Current statusHyperthermia, Fever and Infectious DiseasesDiagnostic and Prognostic Value of Clinical and Laboratory Findings in Cryptococcal MeningitisThe Use of Amphotericin B in Blastomycosis, Cryptococcosis and HistoplasmosisCryptococcal meningitis in Hong KongTORULOSISDie AntimykoticaDie tierischen Parasiten und Pilzinfektionen im zentralen NervensystemCryptococcosis (Torulosis)An antidote to cycloheximide (Acti-dione) poisoningDas kulturell-biochemische und serologische Verhalten der Cryptococcus-GruppeCRYPTOCOCCOSIS (TORULOSIS) : A REPORT OF NINE CASESRESECTION IN PULMONARY CRYPTOCOCCOSIS (TORULOSIS)CRYPTOCOCCUS RENAL INFECTION: REPORT OF A CASE*ALFRED P. SPIVACK, M.D., JAY A. NADEL, M.D., GEORGE M. EISENBERG, D.SC.CRYPTOCOCCUS MENINGITIS ARRESTED WITH AMPHOTERICIN B*EMANUEL APPELBAUM, M.D., F.A.C.P., SINOVIJ SHTOKALKO, M.D.CryptococcosisMykosen der inneren OrganeTORULOSIS IN QUEENSLAND: REPORT OF FOURTEEN CASESTherapy for Pulmonary and Systemic Fungus DiseasesSYSTEMIC CRYPTOCOCCOSIS WITHOUT CENTRAL NERVOUS SYSTEM INVOLVEMENT: A CASE REPORT*R. F. WETTINGFELD, M.D., E. C. H. SCHMIDT, M.D., C. F. NAEGELE, M.D., A. A. DOERNER, M.D., F.A.C.P.CRYPTOCOCCUS MENINGITIS IN A CASE OF CONGENITAL HEMOLYTIC ANEMIA*JOHN B. ATKINSON, M.D., WILLIAM E. DELANEY, M.D., FRANKLIN R. MILLER, M.D.Therapy of the malignant lymphomasTHERAPY OF HUMAN TORULOSIS WITH ACTIDIONE AND “CONTRAMINE”: A REPORT ON TWO CASESCURRENT TREATMENT OF TUBERCULOUS MENINGITIS: A PRELIMINARY REPORT*EUGENE J. DES AUTELS, M.D., F.A.C.P., KARL H. PFUETZE, M.D.PULMONARY TORULOSIS COMPLICATING PULMONARY TUBERCULOSIS TREATED BY RESECTIONMycology 1 July 1952Volume 37, Issue 1Page: 123-154KeywordsBacteriologyCentral nervous systemCryptococcosisLesionsLungsMorbidityMortalityNeurologyNeurosurgerySurgeons Issue Published: 1 July 1952 PDF downloadLoading ...